Oncotarget cover image

Oncotarget

Genes & Cancer: How Ewing Sarcoma Led to Discoveries in Rhabdomyosarcoma

Jun 29, 2022
Learn about the genetic mutations driving Fusion Positive Rhabdomyosarcoma (FPRMS) and the role of KDM3A and ETS1 in promoting the growth and metastasis of Rhabdomyosarcoma. Discover shared disease-promoting pathways with Ewing's sarcoma and potential therapeutic targets for multiple subtypes.
08:01

Podcast summary created with Snipd AI

Quick takeaways

  • P3F-onco-fusion genes drive metastasis in fusion-positive RMS through transcriptional and epigenetic mechanisms.
  • KDM3A ETS1 MCAM axis promotes growth and metastasis in Rhabdomyosarcoma, offering potential therapeutic targets.

Deep dives

Discovery of P3F Mechanisms in Rhabdomyosarcoma

Researchers from the University of Colorado Denver and Schutz Medical Campus identified the P3F-onco-fusion genes as key drivers of the aggressive fusion-positive RMS subtype, leading to metastasis using transcriptional and epigenetic mechanisms. A team of dedicated researchers delved into understanding the molecular pathways behind RMS progression, unveiling the KDM3A ETS1 MCAM axis that promotes growth and metastatic properties in Rhabdomyosarcoma. Through RNA sequencing analysis, the researchers found that KDM3A positively influences the expression of pro-growth and pro-metastatic genes in both fusion-negative and fusion-positive RMS cells, similar to its role in Ewing sarcoma.

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner